In the metastatic BRAF V600 mutant melanoma, the BRAF ctDNA negative-patients at baseline therapy had a high RR to target therapy, while the BRAF-positive patients had a shorter PFS and OS [349]. This evidence concerns the gene BRAF and melanoma.